Dr. Gary Gintant is Senior Group Leader in the Dept. of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, where he heads the Early Preclinical Studies Group. He is actively involved in various cardiac risk assessment / QT interval committees (including the ILSI/HESI Cardiovascular Risk Assessment Committee and Abbott QT Working Group) and has served on various NIH study sections and as advisor to the National Institutes for Drug Abuse regarding cardiac toxicity.